Daiichi Sankyo, Inc. today announced the filing of a supplemental New Drug Application (sNDA) with the United States Food and Drug Administration (FDA) for the combination treatment AZOR(R) (amlodipine and olmesartan medoxomil) as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goal.
The whole story can be read here.
No comments:
Post a Comment